Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Histone Deacetylase (HDAC) Inhibitors Market Size Forecast: How Large Could The Market Become By 2030?

The market for HDAC inhibitors has experienced robust expansion lately, with its value projected to climb from $1.32 billion in 2025 to $1.42 billion in 2026, reflecting a compound annual growth rate of 7.5%. This surge during the preceding period was fueled by heightened research in oncology therapeutics, a developing grasp of epigenetic processes, the broadening scope of clinical investigations, increased financial backing for pharmaceutical research and development, and the accessibility of sophisticated molecular assessment technologies.

The market for histone deacetylase (HDAC) inhibitors is poised for substantial expansion, with projections indicating a surge to $1.89 billion by the year 2030, reflecting a compound annual growth rate of 7.4%. This anticipated growth trajectory during the upcoming forecast period is underpinned by several key factors, including the escalating acceptance of individualized cancer treatment approaches, a notable increase in financial backing for the development of epigenetic drugs, broader exploration of HDAC research within the field of neurology, a heightened demand for therapies designed to target specific disease mechanisms, and a growing number of regulatory endorsements for innovative HDAC inhibitor compounds. Furthermore, significant trends expected to shape this market over the forecast horizon encompass a concentrated effort towards targeted epigenetic therapies, the accelerated development of HDAC inhibitors with enhanced selectivity, a more widespread utilization of combined therapeutic strategies in oncology, an augmented pipeline of drugs within the domain of precision medicine, and a heightened emphasis on drug discovery guided by biomarkers.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18386&type=smp

Histone Deacetylase (HDAC) Inhibitors Market Growth Drivers: What Factors Are Accelerating Expansion?

The increasing prevalence of neurodegenerative conditions is poised to be a significant catalyst for the expansion of the histone deacetylase (HDAC) inhibitors market. These progressive conditions, which involve the deterioration and demise of nerve cells within the brain and spinal cord, result in impairments in both cognitive and motor functions. Prominent examples include Alzheimer’s disease, characterized by memory impairment and a decline in cognitive abilities stemming from the accumulation of amyloid plaques and tau tangles. A confluence of factors, including an aging population, increased life expectancy, genetic predispositions, and environmental influences, contributes to the growing number of neurodegenerative disorders. Research is actively investigating HDAC inhibitors as prospective therapeutic agents for these conditions, owing to their capacity to influence gene expression and offer protection to nerve cells. To illustrate, data from the Centers for Disease Control and Prevention, a U.S. federal agency, indicated in August 2024 that approximately 6.7 million individuals in the United States aged 65 and older were living with Alzheimer’s disease, a figure projected to approach 14 million by the year 2060. Consequently, the escalating occurrence of neurodegenerative disorders is fueling the advancement of the HDAC inhibitors market.

Histone Deacetylase (HDAC) Inhibitors Market Segmentation: How Is The Market Structured Across Key Categories?

The histone deacetylase (hdac) inhibitors market covered in this report is segmented –

1) By Class: Class I HDACs, Class II HDACs, Class III HDACs

2) By Route Of Administration: Oral HDAC Inhibitors, Parenteral HDAC Inhibitors

3) By Application: Oncology, Neurology, Other Applications

4) By End User: Hospitals, Academic And Research Institutes, Pharmaceutical Companies, Other End Users

Subsegments:

1) By Class I HDACs: HDAC1, HDAC2, HDAC3, HDAC8

2) By Class II HDACs: HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10

3) By Class III HDACs (Sirtuins): SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7

Histone Deacetylase (HDAC) Inhibitors Market Trends: What Is Shaping Future Industry Growth?

The leading players within the histone deacetylase (HDAC) inhibitors market are concentrating their efforts on pioneering novel therapeutic approaches, specifically the development of HDAC inhibitors designed for cancer therapy, with the dual objectives of boosting treatment effectiveness and mitigating adverse reactions. Histone deacetylase (HDAC) inhibitors represent a category of medicinal agents employed in oncology. Their mechanism involves obstructing the function of HDAC enzymes, which are typically responsible for cleaving acetyl groups from histone proteins. Such obstruction results in heightened histone acetylation, thereby modifying the chromatin architecture and impacting how genes are expressed. As an illustration, in September of 2023, Shuttle Pharmaceuticals Holdings Inc., an American enterprise dedicated to creating groundbreaking cancer treatments, received new patent grants for HDAC inhibitors targeting cancer from the U.S. Patent and Trademark Office. These cutting-edge inhibitors are specifically engineered to identify and act upon particular HDAC enzymes that play a role in cancer’s advancement, intending to interrupt the abnormal gene expression patterns that facilitate tumor proliferation and spread. The compounds secured by these patents exhibit superior strength and precision, thereby reducing unintended consequences and refining the safety characteristics for individuals undergoing therapeutic interventions.

Histone Deacetylase (HDAC) Inhibitors Market Competitive Landscape And Leading Companies

Major companies operating in the histone deacetylase (hdac) inhibitors market are Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.

Access The Complete Histone Deacetylase (HDAC) Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/histone-deacetylase-hdac-inhibitors-global-market-report

Histone Deacetylase (HDAC) Inhibitors Market Regional Outlook: Where Are The Largest Opportunities Located?

North Americawas the largest region in the histone deacetylase (HDAC) inhibitors market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (hdac) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model